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REPLIKIN  COUNT  CYCLES  IN  MALARIA  AND  METHODS  OF  PREDICTING  INCREASED 
MORTALITY
 
An increase in virulence, morbidity, and/or mortality of a placidium  that causes malaria 
may be predicted by identifying a cycle of Replikin concentration among a plurality of 
isolates of the species of  and identifying a peak in that cycle.  An increase in virulence, 
morbidity, and/or mortality is predicted following the time point or time period when the 
peak is identified.   
This communication is one of four submitted together: 
Genome Replikin CountTM  Predicts Increased Lethality of Resistant Tuberculosis 
Genome Replikin CountTM  Predicts Increased Lethality of Malaria 
Genome Replikin CountTM  Predicts Increased Lethality of Cancer 
Genome Replikin CountTM  Predicts Increased Infectivity/Lethality of Virus 
Replikin Count Cycles Predict Increased Mortality 
A cycle of Replikin concentration or “Replikin cycle” of  may be seen in Supplement 
Figure 1. A Replikin cycle is identified by initially isolating at least four isolates or 
groups of isolates from at least four time points or time periods, for example, an isolate or 
group of isolates may be obtained in 1999, 2001, 2002, and 2004, or may be obtained in 
January, May, September, and December of a given year.  Isolates may be obtained from 
more than four time points or time periods and precision of a Replikin Cycle generally 
will improve with increases in the number of isolates per time point or time period and 
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with increases in the number of time points or time periods.  The Replikin Count of the 
genome or expressed proteins of each isolate is determined.  Replikin Count may be 
determined in a Replikin Peak Gene, in the entire genome, in a particular gene or gene 
segment, or in a particular protein or protein fragment of each of the isolates.  Mean 
Replikin Count for a given time point or given time period is determined if a plurality of 
isolates has been obtained for the given time point or given time period.  Replikin Count 
may then be analyzed per unit time.  A cycle in Replikin concentration is identified by 
four time points or time periods, where the Replikin Count at a second time point or time 
period is higher than at first time point or time period, the Replikin Count at a third time 
point or time period is lower than at second time point or time period, and Replikin Count 
at a fourth time point or time period is higher than at the third time point or time period; 
or where the Replikin Count at a second time point or time period is lower than at first 
time point or time period, the Replikin Count at a third time point or time period is higher 
than at second time point or time period, and Replikin Count at a fourth time point or 
time period is lower than at the third time point or time period.  
 
A peak in a Replikin cycle is identified within the cycle at a second time point or time 
period within a Replikin cycle, wherein the Replikin concentration at a first time point or 
time period immediately preceding the second time point or time period is lower than the 
Replikin concentration at the second time point or time period, and the Replikin 
concentration at a third time point or time period immediately following the second time 
point or time period is lower than the Replikin concentration at the second time point or 
time period.  Replikin peptides of the discovery identified at a peak of the Replikin cycle 
include Replikin peptides identified at or near the peak of the Replikin cycles including 
prior to and subsequent to the precise point of the peak.  A rising portion of a Replikin 
cycle is any point at which trend of Replikin concentration in the Replikin cycle is 
increasing from at least a first time point or time period to at least a second time point or 
time period and can include a peak.  As may be seen in Figures 1-5, an increase in 
virulence, morbidity, or mortality may be predicted following a rising portion or peak in a 
Replikin cycle.   
 
Figure 1 illustrates cycling between 1986 and 2007 of annual mean Replikin 
concentration in the histidine rich protein of Plasmodium falciparum.  P. falciparum is a 
trypanosome that is most commonly associated with malaria.  Two cycles are observable 
at peaks in 1987 and 1999.  A third cycle appears to have begun between 2005 and 2007.  
Publicly available accession numbers at www.pubmed.com containing amino acid 
sequence listings for P. falciparum were queried using the automated FluForecast® 
software (Replikins, Ltd., Boston, MA).  The software analyzed the Replikin Count of 
each available sequence  in Pubmed between 1986 and 2007.  The area of the P. 
falciparum genome observed to have the highest concentration of continuous Replikin 
sequences per 100 amino acids was determined to be the histidine rich protein.  The 
histidine rich proteins include the knob-associated histidine rich protein 
 
Analysis of the mean annual Replikin Count of the histidine rich protein between 1986 
and 2007 revealed two cycles of Replikin Count.  The first cycle was observed from 1986 
to 1995.  The second was observed from 1996 to 2005.  The peak of the first cycle was 
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identified in 1987 with a mean annual Replikin Count of 38.2 and standard deviation of 
±23.5.  The peak of the second cycle was identified in 1999 with an even higher mean 
annual Replikin Count of 62.9 and standard deviation of ±62.9 (branching and stacking 
of Replikin sequences within an amino acid sequence generates a Replikin Count of 
greater than 100 Replikin sequences per 100 amino acids in some sequences).  Both the 
1987 peak and the 1999 peak were observed to be related to higher human mortality.  
Following the 1999 peak, mean annual Replikin Counts were observed to fall to a low of 
7.4 in 2005 with a standard deviation of ±6.5.  Mortality rates likewise fell between 2000 
and 2005.  A third malaria Replikin cycle appears to have begun in 2005 with the 
observed annual mean Replikin Count increasing from 7.4±6.5 in 2005 to 17.2±19 in 
2007.  The beginning of the third cycle provides a prediction that Replikin Count may 
continue to increase along with an increase in malaria mortality rate.  
 
Replikin CountTM Cycling Observed in Other Organisms 
 
The cycling observable for Plasmodium  Falciparum in Figure 1 has also been observed 
in viruses, namely, the H1N1, H2N2, H3N2, H5N1, and H3N8 strains of influenza virus 
and in West Nile virus.  Thus Replikin cycles are observable in both viruses and other 
organisms.  The Replikin concentration of West Nile Virus was earlier found to increase 
annually through two distinct cycles as the virus expanded in the U.S.: the first from 2000 
to 2003, and the second from 2004 to 2007 (p less than 0.001).  Increases in the annual 
number of CDC reported human cases followed each of the virus Replikin concentration 
increases.  Similar correlations also have been shown for Replikin concentrations and 
human mortality in an influenza H5N1 cycle between 1997 and 2007. The data for 
Supplement Figure 1 are seen in Table 1 below.  Mean annual Replikin Count, standard 
deviation, significance of annual mean Replikin Count to the lowest annual mean 
Replikin Count and to the previous annual mean Replikin Count, and number of 
accession numbers analyzed per annum is provided.   
 
Supplement Table 1- Malaria (Pl Falciparum) 
Year 
Mean 
Replikin 
Count 
Standard 
Deviation 
Significance 
(compared to 
lowest value) 
Significance  
(compared to 
previous year) 
Number of 
Accession 
Records for 
malaria isolates 
1986 15.9 15.2 low>.5  6 
1987 38.2 23.5 low<.005 <.02 11 
1988      
1989 13.9 0  <.005 1 
1990 5.2 0   1 
1991      
1992 13 18.2 >.5 <.2 9 
1993      
1994      
1995 2.4 0  <.1 1 
1996 8.7 1.2 <.01 <.01 3 
1997      
1998 24.1 16.7 <.01 <.04 7 
1999 62.9 62.9 <.2 <.24 4 
2000 33.3 24.7 <.3 <.4 3 
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2001      
2002 18 29 >.5 <.3 13 
2003 28.4 3 <.001 <.2 7 
2004 17 0 <.001  1 
2005 7.4 6.5 <.05 <.02 5 
2006      
2007 17.2 19 >.5 <.2 8 
As is seen in Supplement Figure 1 and Supplement Table 1 above and as also seen in 
Supplement Figure 2 and Supplement Table 3 below, changes in malaria virulence and 
mortality may be predicted by identifying a peak within an identified cycle in the 
Replikin concentration of isolates of a plurality of the trypanosome and predicting an 
increase in the virulence, morbidity, and/or mortality of a trypanosome of the same 
species isolated at a time point or time period subsequent to the time point or time period 
of the identified peak in the cycle of Replikin concentration.  In contrast to Figures 3 and 
4 for West Nile virus and influenza, morbidity data is not reflected in the analysis of 
malaria in Figure 1 and is not contained in Figure 2.  Use of mortality data and not 
morbidity data in these Figures and their related analysis and tables is based on the 
researcher’s understanding that morbidity data in malaria is generally unreliable while 
mortality data is considered more reliable.  While the analysis of Supplement Figure 1 
and the data in Supplement Figure 2 demonstrate a relationship between Replikin Count 
in P. falciparum and mortality, the skilled artisan will understand that the relationship 
would also be expected to extend to morbidity and general virulence in malaria just as it 
has in West Nile virus (see Supplement Figure 3) and influenza.   
 
Cyclic increases in Replikin concentration in the genome can be a mechanism of 
expansion of an infectious organism into a territory. The Replikin concentration in each 
Replikin Peak Gene of each Replikin cycle apparently builds on the previous one.  In 
both the mosquito-borne West Nile Virus and mosquito-borne malaria trypanosomes this 
build-up probably occurs during winter seasons, dry seasons, or otherwise dormant 
periods.  Timely, repeated analyses of cyclic changes in the organism’s Replikin structure 
is useful to bring current the targets for the chemical synthesis of Replikin vaccines 
having a best fit for emerging pathogens having increased virulence, morbidity, and/or 
mortality. These strain-specific vaccines may be manufactured in seven days as has been 
demonstrate with a 91% protection of shrimp against the lethal Taura Syndrome Virus. its 
entirety by reference).   
 
Malaria trypanosomes were found to have the highest Replikin counts seen to date in any 
infectious organisms - up to twenty times those in influenza and West Nile Virus.  
Consistent with these high counts, trypanosomes have one of the highest replication rates 
in nature.  This property may account in part for the resistance of malaria to previous 
attempts at vaccination.  The discovery of the relation of Replikin sequences to rapid 
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replication offers a new approach, and means, to inhibit rapid replication in 
malaria  
Figure 2 illustrates that mortality rates per 1000 clinical cases of malaria in humans 
generally correlate with annual mean Replikin Count in sequences of the P. falciparum 
ATP-ase enzyme publicly available at www.pubmed.com.  Mean annual Replikin Counts 
of P. falciparum ATP-ase increased from 1997 to 1998 along with an increase in 
mortality per malaria case from 1997 and 1998 to 1999.  The mean annual Replikin 
Count of P. falciparum ATP-ase decreased from 1998 to 2007 along with the mortality 
rates from 1999 to 2005 (consistent mortality data is considered presently available only 
through 2005).  Mortality rates per 1000 human cases of malaria for 1997 to 2005 were 
as follows:  1997 mortality rate was 17; 1998 mortality rate was 17; 1999 mortality rate 
was 19; 2000 mortality rate was 16; 2001 mortality rate was 13; 2002 mortality rate was 
10; 2003 mortality rate was 10; 2004 mortality rate was 9; and 2005 mortality rate was 9.  
Mortality rates are recorded as declared by the World Health Organization.  See 
www.who.int. . 
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Analysis of Replikin Count in Malaria to Predict Increased Mortality 
 
The authors analyzed publicly available sequences for isolates of P. falciparum from 
PubMed using proprietary search tool software (ReplikinForecast™ available in the 
United States from REPLIKINS LLC, Boston, MA) from years 1986 to 2007 and 
determined the mean Replikin Count for the histidine-rich protein of all isolates available 
in each of those years.  The authors then compared the mean Replikin Count for each 
year with changes in mortality as reported by the World Health Organization 
 
A list of the accession numbers analyzed for the presence and concentration of Replikin 
sequences is provided in Supplement Table 2 below.  The mean Replikin Count for each 
year is provided following the list of accession numbers from isolates in each 
corresponding year.  Standard deviation and significance as compared to the mean 
Replikin Count of the previous year and of the lowest mean Replikin Count within the 
data set are also provided along with the mean Replikin Count for each year 
Analysis of Replikin Count in Malaria ATP­ase to Predict Increased Mortality 
The authors analyzed publicly available sequences of the ATP-ase enzyme of isolates of 
P. falciparum at www.pubmed.com.  The data is summarized below in Supplement Table 
3 and illustrated above in Supplement Figure 2.  The data illustrate that mortality rates 
per 1000 clinical cases of malaria in humans correlate with annual mean Replikin Count 
in sequences of the P. falciparum ATP-ase enzyme publicly available at 
www.pubmed.com.  Replikin Counts of The Replikin Count of P. falciparum ATP-ase 
increased from 1997 to 1998 along with an increase in mortality per malaria case from 
1997 and 1998 to 1999.  The Replikin Count of P. falciparum ATP-ase decreased from 
1998 to 2007 along with mortality rates from 1999 to 2005 (consistent mortality presently 
available only through 2005).  Mortality rates per 1000 human cases of malaria for 1997 
to 2005 were as follows:  1997 mortality rate was 17; 1998 mortality rate was 17; 1999 
mortality rate was 19; 2000 mortality rate was 16; 2001 mortality rate was 13; 2002 
mortality rate was 10; 2003 mortality rate was 10; 2004 mortality rate was 9; and 2005 
mortality rate was 9.  Mortality rates are recorded as declared by the World Health 
Organization.  See www.who.int 
 
High malaria morbidity and mortality rates occurred in the late 1990s and were thought to 
be due to a decreased effectiveness of anti-malarials.  ATP-ase is a primary target of 
arteminisin treatment of malaria.  With increased use of arteminisin, and improved public 
health measures, morbidity and mortality rates declined from 1999 to 2005 
 
 
 
 
 
Table 3 
Year Mean 
Replikin 
Count in 
Standard 
Deviation 
Mortality 
Rate per 
1000 
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P. 
falciparum 
ATP-ase 
Malaria 
Cases 
1997 19 7.7 17 
1998 19.4 16.6 17 
1999 16.1 9.1 19 
2000 11.2 10.5 16 
2001 7.7 8.1 13 
2002 12.7 9.9 10 
2003 3.3 2.5 10 
2004 4.2 4.6 9 
2005 6.3 3.9 9 
2006 3.4 2.6  
2007 6.2 8.4  
Analysis of Replikin Count Cycles in Malaria to Predict Entry into Geographical 
Regions 
The phenomenon of geographical expansion, seen with West Nile Virus entry into North 
America in 2000 and expansion to the present, also applies to malaria and other 
pathogens.  Analysis of the Replikin concentration of a Replikin Peak Gene, histidine-
rich protein, or ATP-ase of P. falciparum that demonstrates Replikin concentration cycles 
may provide a prediction of an expansion of P. falciparum mortality and/or morbidity.  
For example, if a Replikin concentration cycle based on isolates from a particular region 
of a region demonstrate a prolonged rise in mean annual Replikin Count or a peak 
following a rise in mean annual Replikin Count, the significant rise or peak predicts an 
expansion of the mortality rate or morbidity rate of that isolate into contiguous or nearby 
regions that until the significant rise or peak in Replikin Count did not experience the 
mortality rate or morbidity rate of the particular region.     
A cycle of Replikin concentration is established in the Sahel region of Africa with two 
peaks at years 2 and 7.  The second peak at year 7 is significantly higher than the first 
peak at year 2 with a p value of 0.01.  The Sahel region between years 0 and 7 has 
experienced a higher rate of mortality than more southerly regions.  Based on the higher 
peak at year 7, it is predicted that the mortality from malaria will increase in the region 
contiguous to the south of the Sahel.  A plurality of Replikin sequences are isolated from 
year 7 isolates.  Replikins that have been conserved between years 0 and 7 are selected as 
vaccines for malaria in the Sahel and contiguous regions to the south.  Replikins that are 
new in year 7 are likewise selected as vaccines.  
 Analysis of Replikin Count in Malaria to Predict Increased Mortality 
The authors analyzed publicly available sequences for isolates of P. falciparum from 
PubMed using proprietary search tool software (ReplikinForecast™ available in the 
United States from REPLIKINS LLC, Boston, MA) from years 1986 to 2007 and 
determined the mean Replikin Count for the histidine-rich protein of all isolates available 
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in each of those years.  The authors then compared the mean Replikin Count for each 
year with changes in mortality as reported by the World Health Organization.  
 
A list of the accession numbers analyzed for the presence and concentration of Replikin 
sequences is provided in Supplement Table 2 below.  The mean Replikin Count for each 
year is provided following the list of accession numbers from isolates in each 
corresponding year.  Standard deviation and significance as compared to the mean 
Replikin Count of the previous year and of the lowest mean Replikin Count within the 
data set are also provided along with the mean Replikin Count for each year.  
 
Analysis of the annual mean Replikin Count of the histidine rich protein between 1986 
and 2007 revealed two cycles of Replikin Count.  The beginning of the third cycle 
provides a prediction that Replikin Count may continue to increase along with an 
increase in malaria mortality rate.  The data is graphically illustrated in Supplement 
Figure 1 and summarized in Supplement Table 1 above.  
 
Analysis of Replikin Count in Malaria ATP­ase to Predict Increased Mortality 
 
The authors analyzed publicly available sequences of the ATP-ase enzyme of isolates of 
P. falciparum at www.pubmed.com.  The data is summarized below in Supplement Table 
3 and illustrated above in Supplement Figure 2.  The data illustrate that mortality rates 
per 1000 clinical cases of malaria in humans correlate with annual mean Replikin Count 
in sequences of the P. falciparum ATP-ase enzyme publicly available at 
www.pubmed.com.  Replikin Counts of The Replikin Count of P. falciparum ATP-ase 
increased from 1997 to 1998 along with an increase in mortality per malaria case from 
1997 and 1998 to 1999.  The Replikin Count of P. falciparum ATP-ase decreased from 
1998 to 2007 along with mortality rates from 1999 to 2005 (consistent mortality presently 
available only through 2005).  Mortality rates per 1000 human cases of malaria for 1997 
to 2005 were as follows:  1997 mortality rate was 17; 1998 mortality rate was 17; 1999 
mortality rate was 19; 2000 mortality rate was 16; 2001 mortality rate was 13; 2002 
mortality rate was 10; 2003 mortality rate was 10; 2004 mortality rate was 9; and 2005 
mortality rate was 9.  Mortality rates are recorded as declared by the World Health 
Organization.  See www.who.intHigh malaria morbidity and mortality rates occurred in 
the late 1990s and were thought to be due to adaptation of the microorganism and 
decreased effectiveness of anti-malarials.  ATP-ase is a primary target of arteminisin 
treatment of malaria.  With increased use of arteminisin, and improved public health 
measures, morbidity and mortality rates declined from 1999 to 2005.   
Table 3 
Year Mean 
Replikin 
Count in 
P. 
falciparum 
ATP-ase 
Standard 
Deviation 
Mortality 
Rate per 
1000 
Malaria 
Cases 
1997 19 7.7 17 
1998 19.4 16.6 17 
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1999 16.1 9.1 19 
2000 11.2 10.5 16 
2001 7.7 8.1 13 
2002 12.7 9.9 10 
2003 3.3 2.5 10 
2004 4.2 4.6 9 
2005 6.3 3.9 9 
2006 3.4 2.6  
2007 6.2 8.4  
Analysis of Replikin Count Cycles in Malaria to Predict Entry into Geographical 
Regions 
The phenomenon of geographical expansion also applies to malaria and other pathogens.  
Analysis of the Replikin concentration of a Replikin Peak Gene, histidine-rich protein, or 
ATP-ase of P. falciparum that demonstrates Replikin concentration cycles may provide a 
prediction of an expansion of P. falciparum mortality and/or morbidity.  For example, if a 
Replikin concentration cycle based on isolates from a particular region of a region 
demonstrate a prolonged rise in mean annual Replikin Count or a peak following a rise in 
mean annual Replikin Count, the significant rise or peak predicts an expansion of the 
mortality rate or morbidity rate of that isolate into contiguous or nearby regions that until 
the significant rise or peak in Replikin Count did not experience the mortality rate or 
morbidity rate of the particular region 
A cycle of Replikin concentration is established in the Sahel region of Africa with two 
peaks at years 2 and 7.  The second peak at year 7 is significantly higher than the first 
peak at year 2 with a p value of 0.01.  The Sahel region between years 0 and 7 has 
experienced a higher rate of mortality than more southerly regions.  Based on the higher 
peak at year 7, it is predicted that the mortality from malaria will increase in the region 
contiguous to the south of the Sahel.  A plurality of Replikin sequences are isolated from 
year 7 isolates.  Replikins that have been conserved between years 0 and 7 are selected as 
vaccines for malaria in the Sahel and contiguous regions to the south.  Replikins that are 
new in year 7 are likewise selected as vaccines.  A mixture of these Replikin sequences is 
combined with a pharmaceutically acceptable carrier and/or adjuvant and administered to 
a subject to produce an immune response to treat and/or protect against malaria predicted 
to have a higher mortality rate following the dry season in year 8 in the Sahel and in its 
contiguous regions to the south.  
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